Axsome Therapeutics
AXSM
505 hedge funds and large institutions have $9.34B invested in Axsome Therapeutics in 2026 Q2 according to their latest regulatory filings, with 139 funds opening new positions, 160 increasing their positions, 159 reducing their positions, and 40 closing their positions.
248% more first-time investments, than exits
New positions opened: 139 | Existing positions closed: 40
46% more capital invested
Capital invested by funds: $6.41B → $9.34B (+$2.94B)
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
23% more funds holding
Funds holding: 410 → 505 (+95)
1% more repeat investments, than reductions
Existing positions increased: 160 | Existing positions reduced: 159
0.13% more ownership
Funds ownership: 74.12% → 74.24% (+0.13%)
14% less call options, than puts
Call options by funds: $247M | Put options by funds: $287M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$116M |
| 2 |
Jane Street
New York
|
+$86.7M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$81.1M |
| 4 |
Two Sigma Investments
New York
|
+$75.2M |
| 5 |
Morgan Stanley
New York
|
+$71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$175M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$146M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$107M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$104M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$89.2M |
AXSM Hedge Fund Activity: Q2 2026 in Review
505 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2026, worth a combined $9.34B — up 46% from $6.41B a quarter earlier.
Buyers outnumbered sellers: 139 funds opened new AXSM positions and 40 closed out — a net gain of 99 holders — while 160 added to existing stakes and 159 trimmed.
The largest buyer was Millennium Management, adding an estimated $116M. The largest seller was BlackRock, cutting an estimated $175M.
- 505 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2026, up from 410 in Q1 2026.
- Funds reported $9.34B of Axsome Therapeutics stock for Q2 2026, up 46% quarter-over-quarter.
- 139 funds opened new Axsome Therapeutics positions in Q2 2026 and 40 closed out, a net change of +99 holders.
- The largest Axsome Therapeutics buyer in Q2 2026 was Millennium Management, an estimated $116M added.
- The largest Axsome Therapeutics seller in Q2 2026 was BlackRock, an estimated $175M sold.
Based on aggregated 13F filings for Q2 2026.